Literature DB >> 21602182

Renal involvement in a large cohort of Chinese patients with Castleman disease.

Damin Xu1, Jicheng Lv, Yujun Dong, Suxia Wang, Tao Su, Fude Zhou, Wanzhong Zou, Minghui Zhao, Hong Zhang.   

Abstract

BACKGROUND: The association of kidney disease with Castleman disease (CD) is uncommon. To date, most studies have been based on single-case reports. Here, we describe renal involvement in CD in a large Chinese cohort.
METHODS: Seventy-six CD patients were identified in one clinical center. Clinical and pathological characteristics of patients with renal involvement were described, which were also compared with cases identified through a systematic literature review.
RESULTS: Nineteen patients (25%) exhibited renal involvement. Patients with multicentric clinical type (59 versus 0%) or plasma cell (PC)/mixed cellularity histological variant (61.5 versus 6%) were more likely to have renal involvement (P < 0.001). Proteinuria (with 7/19 reaching nephrotic range) and acute renal failure (12/19, 63%) were the main clinical presentations. Kidney biopsy revealed various glomerular diseases (10/11) and interstitial nephritis (1/11), while with 'thrombotic microangiopathy-like' lesions were the most common pathological characteristics (6/11, 55%). This contrasted significantly with the literature in which amyloidosis was the most reported. Renal outcomes responded well to chemotherapy. Nine (9/12, 75%) patients with acute renal failure recovered completely, one recovered partially. Overall, only three (3/19, 16%) patients progressed to end-stage kidney disease. Renal involvement did not influence survival rate (log-rank test, P = 0.73) in the follow-up.
CONCLUSIONS: CD with multicentric type and PC or mixed cellularity variant are often associated with renal complications. Thrombotic microangiopathy-like lesions are the most common pathological characteristics. Chemotherapy can reverse kidney damage in most cases.

Entities:  

Mesh:

Year:  2011        PMID: 21602182     DOI: 10.1093/ndt/gfr245

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  25 in total

1.  Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Authors:  Lucie M Turcotte; Colleen K Correll; Robyn C Reed; Christopher L Moertel
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

2.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

3.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

4.  Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Shunsuke Yamada; Akihiro Tsuchimoto; Yoshiki Kaizu; Masatomo Taniguchi; Kosuke Masutani; Hiroshi Tsukamoto; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-29

5.  Focal segmental glomerulosclerosis associated with cutaneous and systemic plasmacytosis.

Authors:  Shinsuke Isobe; Naro Ohashi; Naoko Katahashi; Sayaka Ishigaki; Naoko Tsuji; Takayuki Tsuji; Akihiko Kato; Yoshihide Fujigaki; Akira Shimizu; Hideo Yasuda
Journal:  CEN Case Rep       Date:  2017-09-22

6.  Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Authors:  Toshikazu Ozeki; Masashi Tsuji; Junichiro Yamamoto; Chisato Shigematsu; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2018-05-15

7.  Retrospective analysis of 45 cases of localized retroperitoneal Castleman disease from a single center.

Authors:  Jian-Qiang Tang; He-Kai Chen; Xin Wang; Ming-Yue Wang; Yan Xiong; He Wang; Yin-Mo Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

8.  A Case of Retroperitoneal Castleman's Disease and an Update on the Latest Evidence.

Authors:  Eleftherios Spartalis; Petros Charalampoudis; Apostolos Kandilis; Antonios Athanasiou; Petros Tsaparas; Athanasios Voutsarakis; Ioannis D Kostakis; Dimitrios Dimitroulis; Evanthia Svolou; Penelope Korkolopoulou; Nikolaos Nikiteas; Gregory Kouraklis
Journal:  Case Rep Surg       Date:  2014-11-05

Review 9.  Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.

Authors:  Ryosuke Saiki; Kan Katayama; Yosuke Hirabayashi; Keiko Oda; Mika Fujimoto; Tomohiro Murata; Ayako Nakajima; Kaoru Dohi
Journal:  BMC Nephrol       Date:  2021-06-09       Impact factor: 2.388

10.  The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.

Authors:  Ikuko Kubokawa; Akihiro Yachie; Akira Hayakawa; Satoshi Hirase; Nobuyuki Yamamoto; Takeshi Mori; Tomoko Yanai; Yasuhiro Takeshima; Eiryu Kyo; Goichi Kageyama; Hiroshi Nagai; Keiichiro Uehara; Masaru Kojima; Kazumoto Iijima
Journal:  BMC Pediatr       Date:  2014-06-02       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.